Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab

References

• Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, et al. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet. 1995;10:330–6.
   PubMed Web of Science ®Google Scholar
• Deere M, Sanford T, Francomano CA, Daniels K, Hecht JT. Identification of nine novel mutations in cartilage oligomeric matrix protein in patients with pseudoachondroplasia and multi-ple epiphyseal dysplasia. Am J Med Genet. 1999;85:486–90.
   Google Scholar
• Mabuchi A, Haga N, Ikeda T, Manabe N, Ohashi H, Takatori Y, et al. Novel mutation in exon 18 of the cartilage oligomeric matrix protein gene causes a severe pseudoachondroplasia. Am J Med Genet. 2001;104:135–9.
   PubMedGoogle Scholar
• Briggs MD, Chapman KL. Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlations. Hum Mutat. 2002;19: 465–78.
   PubMed Web of Science ®Google Scholar
• Mabuchi A, Manabe N, Haga N, Kitoh H, Ikeda T, Kawaji H, et al. Novel types of COMP mutations and genotype-phenotype association in pseudoachondroplasia and multiple epiphyseal dysplasia. Hum Genet. 2003;112:84–90.
   PubMedGoogle Scholar
• Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum. 1998;41:997–1006.
   Google Scholar
• Dragomir AD, Kraus VB, Renner JB, Luta G, Clark A, Vilim V, et al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage. 2002;10:687–91.
   PubMed Web of Science ®Google Scholar
• Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteo-arthritis. Osteoarthritis Cartilage. 2002;10:707–13.
   PubMed Web of Science ®Google Scholar
• Vilim V, Vytasek R, Olejarova M, Machacek S, Gatterova J, Prochazka B, et al. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2001;9:612–8.
   PubMed Web of Science ®Google Scholar
• Skoumal M, Kolarz G, Klingler A. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol. 2003;32:156–61.
   Google Scholar
• Urakami T, Manki A, Inoue T, Oda M, Tanaka H, Morishima T. Clinical significance of decreased serum concentration of carti-lage oligomeric matrix protein in systemic juvenile idiopathic arthritis. J Rheumatol. 2006;33:996–1000.
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M. Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis. Mod Rheumatol. 2004;14:12–7.
   PubMedGoogle Scholar
• Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-inter-leukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–25.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371: 998–1006.
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005;28:231–8.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619–26.
   PubMedGoogle Scholar
• Petty RE. Classification of childhood arthritis: a work in progress. Baillieres Clin Rheumatol. 1998;12:181–90.
   PubMedGoogle Scholar
• Wagner E, Ammer K, Kolarz G, Krajnc I, Palkonyai E, Scherak 0, et al. Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int. 2007;27: 1041–8.
   Google Scholar
• Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol. 1992;31:583–91.
   PubMedGoogle Scholar
• Spitznagel L, Nitsche DP, Paulsson M, Maurer P, Zaucke F. Characterization of a pseudoachondroplasia-associated mutation (His587 - Arg) in the C-terminal, collagen-binding domain of cartilage oligomeric matrix protein (COMP). Biochem J. 2004; 377:479–87.
   Google Scholar
• Bjamason R, Andersson B, Kim HS, Olsson B, Swolin-Eide D, Wickelgren R, et al. Cartilage oligomeric matrix protein increases in serum after the start of growth hormone treatment in prepu-bertal children. J Clin Endocrinol Metab. 2004;89:5156–60.
   Google Scholar
• Sugiyama E. Role of matrix metalloproteinase-3 in joint destruc-tion in rheumatoid arthritis. Clin Calcium. 2007;17:528–34.
   PubMedGoogle Scholar
• Pagani F, Francucci CM, Moro L. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest. 2005;28:8–13.
   Google Scholar
• Camozzi V, Tossi A, Simoni E, Pagani F, Francucci CM, Moro L. Role of biochemical markers of bone remodeling in clinical practice. J Endocrinol Invest. 2007;30:13–7.
   PubMedGoogle Scholar